新制度明确了适用范围，涵盖公司及其实际控制的各级下属企业，参股公司融资担保行为可参照执行。 融资担保形式多样，包括一般保证、连带责任保证、抵押、质押等，也包含隐性担保，但不包括房地产 公司为购房人按揭贷款提供的阶段性担保。 制度对担保审批权限作出详细规定。各级企业对外担保应在公司股东会审议批准的年度担保事项内，超 出部分需报董事会审议。特定情形下，如单笔担保额超公司最近一期经审计净资产10%等七种情况，需 董事会审议通过后提交股东会审议，其中最近十二个月内担保金额累计超公司最近一期经审计总资产 30%这一事项，需经出席会议股东所持表决权的三分之二以上通过。公司提供担保，需全体董事过半数 审议通过，且经出席董事会会议的三分之二以上董事同意并决议，同时及时对外披露。 对于担保对象和担保比例，各级企业原则上只能对具备持续经营和偿债能力的子公司或参股公司担保， 不得对不具备持续经营能力的公司担保，特殊情况需经董事会或股东会审议。应严格按持股比例担保， 对子公司确需超股比担保的，需经审批并由小股东等提供反担保。 8月30日，深圳华侨城股份发布公告，披露了2025年8月28日修订的《融资担保管理制度》，旨在规范公 司融资 ...

Summary of Key Points Core Viewpoint - The company has decided to cancel a previously approved guarantee of up to 50 million RMB for its subsidiary, which will help in better managing financing guarantees without negatively impacting its operations or long-term interests [1][2]. Group 1: Guarantee Situation Overview - The company approved a financing credit of up to 50 million RMB for its subsidiary, with a joint liability guarantee provided by another subsidiary [1]. - The guarantee was related to a loan application made by Beijing Huasu Pharmaceutical Co., Ltd. to Beijing Bank [1]. Group 2: Cancellation of Guarantee - The cancellation of the 50 million RMB guarantee is aimed at effectively managing the external guarantee limits and aligning with the funding needs of the company and its subsidiaries [2]. - The cancellation will not adversely affect the company's normal operations or business development [2]. Group 3: Total Guarantee Amount and Status - After the cancellation, the total guarantee amount for the company and its subsidiaries stands at 896 million RMB, which is 56.41% of the latest audited net assets and 24.14% of total assets [3]. - The total balance of external guarantees is 552.38 million RMB, accounting for 34.78% of the latest audited net assets, with no overdue guarantees or litigation issues reported [3].

Group 1 - The company held the 15th meeting of the 10th Supervisory Board on June 13, 2025, with all three supervisors participating in the voting, which complied with relevant regulations [2][4] - The Supervisory Board approved the financial write-off of asset losses, with a total original value of inventory and fixed assets amounting to 1,789,961.56 yuan and an estimated loss of 978,888.18 yuan, impacting the total profit for 2024 by 825,135.58 yuan [3][4] - The financial write-off will not affect the company's profit and loss for the year 2025, as the impact has already been accounted for in previous years [3] Group 2 - The company announced the proposed cancellation of its subsidiary, Guangxi Wuzhou Zhongheng Pharmaceutical (Hong Kong) Co., Ltd., during the 29th meeting of the 10th Board of Directors held on June 13, 2025 [7][12] - The reason for the cancellation is that the subsidiary has not engaged in substantial operations since its establishment, and the company aims to optimize its organizational structure and improve operational efficiency [8] - The cancellation will not involve personnel arrangements and is not expected to have a significant impact on the company's financial and operational status [9] Group 3 - The Board of Directors approved the establishment of the "Overseas Investment Management Measures" and the "Financing Guarantee Management Measures," as well as the revision of the "Financing Management System" [13][15][16] - All resolutions passed with unanimous support from the board members, indicating strong consensus on these governance measures [14][15]